Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1997 2
1998 3
1999 3
2000 2
2001 5
2002 5
2003 3
2004 4
2005 11
2006 15
2007 24
2008 32
2009 27
2010 28
2011 40
2012 36
2013 59
2014 60
2015 51
2016 70
2017 59
2018 46
2019 55
2020 66
2021 50
2022 43
2023 44
2024 46
2025 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

790 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: cho sg. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Free article. Clinical Trial.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Among authors: cho sg. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
The tools are ready, are we?
Cho SG, Jabin Z, Lee C, Bom HH. Cho SG, et al. J Nucl Cardiol. 2019 Apr;26(2):557-560. doi: 10.1007/s12350-017-1032-7. Epub 2017 Aug 21. J Nucl Cardiol. 2019. PMID: 28828735 No abstract available.
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Among authors: cho sg. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. Nat Cancer. 2025. PMID: 40097657 Free PMC article. Clinical Trial.
Color-tuning of natural variants of heliorhodopsin.
Kim SH, Chuon K, Cho SG, Choi A, Meas S, Cho HS, Jung KH. Kim SH, et al. Among authors: cho sg. Sci Rep. 2021 Jan 13;11(1):854. doi: 10.1038/s41598-020-72125-0. Sci Rep. 2021. PMID: 33441566 Free PMC article.
Role of RhoA-ROCK signaling in Parkinson's disease.
Iyer M, Subramaniam MD, Venkatesan D, Cho SG, Ryding M, Meyer M, Vellingiri B. Iyer M, et al. Among authors: cho sg. Eur J Pharmacol. 2021 Mar 5;894:173815. doi: 10.1016/j.ejphar.2020.173815. Epub 2020 Dec 17. Eur J Pharmacol. 2021. PMID: 33345850 Review.
790 results